

Effects of Perioperative Transcutaneous Electrical Acupoint Stimulation on Monocytic HLA-DR Expression in Patients undergoing Coronary Artery Bypass Grafting with Cardiopulmonary Bypass: Study Protocol for a Double-blind Randomized Controlled Trial

Wen-ting Chen

Anesthesiology department, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

Jin-feng Wei

Guangdong Cardiovascular Institute & Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, China

Lan Wang

Anesthesiology department, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

Deng-wen Zhang

Guangdong Cardiovascular Institute & Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, China

Wei Tang

Anesthesiology department, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

Jian Wang

Anesthesiology Department, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

Yue Yong

Anesthesiology Department, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

Jing Wang

Anesthesiology Department, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

Ya-lan Zhou

Anesthesiology Department, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

Lan Yuan

Anesthesiology Department, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

Guo-qiang Fu

Anesthesiology Department, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

Sheng Wang

Guangdong Cardiovascular Institute & Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, China <https://orcid.org/0000-0003-0065-0102>

Jian-gang Song (✉ songjg1993@126.com)

<https://orcid.org/0000-0002-9485-0908>

Study protocol

Keywords: CABG, TEAS, immunosuppression, mHLA-DR

Posted Date: November 7th, 2019

DOI: <https://doi.org/10.21203/rs.2.84/v3>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on December 30th, 2019. See the published version at <https://doi.org/10.1186/s13063-019-3889-z>.

Abstract

Background: Cardiac surgery involving cardiopulmonary bypass (CPB) is known to be associated with a transient postoperative immunosuppression. When severe and persistent, this immune dysfunction predisposes patients to infectious complications, which contributes to a prolonged stay in the intensive care unit (ICU), even mortality. The effective prevention and treatment methods are still lacking. Recent studies revealed that acupuncture related techniques, such as electroacupuncture (EA) and transcutaneous electrical acupoint stimulation (TEAS), are able to produce effective cardioprotection and immunomodulation in adult and pediatric patients undergoing cardiac surgery with CPB, which leads to enhanced recovery. However, whether perioperative application of TEAS, a non-invasive technique, is able to improve immunosuppression of the patients with post cardiosurgical conditions is unknown. Thus, as a preliminary study, the main objective is to evaluate the effects of TEAS on the postoperative expression of monocytic human leukocyte antigen (-D related) (mHLA-DR), a standardized “global” biomarker of injury or sepsis-associated immunosuppression, in patients receiving on-pump Coronary Artery Bypass Grafting (CABG).

Methods: This clinical study was a single-center clinical trial. The 88 patients scheduled to receive CABG under CPB will be randomized into 2 groups: the group of TEAS, and the group of transcutaneous acupoint pseudo - electric stimulation (Sham TEAS). Monocytic HLA-DR expression serves as a primary endpoint, and other laboratory parameters (e.g. IL-6, IL-10) and clinical outcomes (e.g. postoperative infectious complications, ICU stay time, and mortality) as the secondary endpoints. In addition, immune indicators, such as high mobility group protein 1 (HMGB1) and regulatory T cell (Treg) will also be measured.

Discussion: The current study is a preliminary mono-centric clinical trial with a non-clinical primary endpoint, expression of mHLA-DR, aiming at determining whether perioperative application of TEAS has a potential to reverse CABG-associated immunosuppression. Although the immediate clinical impact of this study is limited, its results would inform further large sample clinical trial with using relevant patient-centered clinical outcomes as primary endpoints.

Background

Cardiac surgery involving cardiopulmonary bypass (CPB) is known to be associated with immune dysfunctions characterized by initial pro-inflammatory response and subsequent anti-inflammatory response^[1]. *If the following anti-inflammatory response is persistent and severe, it will lead to a long-lasting immunosuppressive state, which is considered to result in an increased susceptibility to postoperative infectious complications, such as pneumonia or impaired wound healing, and therefore responsible for a prolonged stay in the intensive care unit (ICU), even mortality^[2-5].*

During CPB surgery, the exposure of blood to nonphysiological surfaces of the CPB apparatus^[6], cardiac arrest and ischemia/reperfusion injury of organs^[7], and translocation of endotoxin (lipopolysaccharide,

LPS) across the ischemic gut wall^[8-10] trigger a pronounced pro-inflammatory response, which is characterized by circulating cytokines, activation of endothelial cells and neutrophils, complement activation, circulating arachidonic acid metabolites, platelet-activating factors, and endothelins^[11, 12]. As a physiologic countermeasure to ameliorate this harmful overactivation of innate immunity, a compensatory anti-inflammatory response often follows, which is known to cause a transient immunosuppression. *It comprises secretion of anti-inflammatory cytokines such as interleukin-10 by monocytes and T cells, down-regulation of inflammatory cell surface receptors on neutrophils, impaired monocytic response to bacterial endotoxins^[13, 14], reduced production of interferon (IFN)- γ , interleukin (IL)-2, and tumor necrosis factor (TNF)- α , as well as peripheral blood mononuclear cell (PBMC) proliferation in response to stimulation with phytohemagglutinin^[15].* Generally speaking, this immunosuppression is temporary and can be restored to normal. However, when serious and persistent, this immune imbalance is considered to contribute to postoperative infectious complications. Unfortunately, the counterbalancing long-lasting immunosuppressive responses still remain a clinical challenge.

Acupuncture is an ancient, non-drug treatment technology originating in China, which has been widely used in the world. Recently, more and more studies revealed that acupuncture was able to effectively regulate the function of immune system, and this technique had been clinically regarded as one of main or adjuvant therapy measures for some immune related diseases (e.g., asthma, allergic rhinitis and rheumatic arthritis, etc.)^[16-18]. In recent years, acupuncture-related techniques began to be applied to cardiac surgery for better recovery. Yang et al^[19] have shown that for adult patients undergoing heart valve replacements, electro-acupuncture (EA) pretreatment can alleviate cardiac ischemia-reperfusion injury indicated by reduced overall serum troponin I release and dosage of inotropic drug use after surgery. Also, ICU stay time was shortened. Subsequently, pretreatment of transcutaneous electric acupoint stimulation (TEAS), a non-invasive acupoint stimulation technique, produces similar cardioprotective effects in pediatric patients undergoing cardiac surgery. Moreover, alleviated inflammation indicated by reduced C-reactive protein level in the early postoperative period was observed^[20].

Experimental studies also demonstrate EA at Zusanli (ST36) acupoint suppresses surgical trauma stress-induced lymphocyte apoptosis^[21] and increase lymphocyte proliferation and IL-2 production of surgically traumatized rat^[22-24] and IFN- γ production of the spleen in mice^[25]. Wang et al further indicated that EA administration after surgical trauma increased Th1 cytokine protein and mRNA expression (IL-2 and IFN- γ), and suppressed Th2 cytokine protein and mRNA expression (IL-4 and IL-10), involving the signaling pathways of ERK1/2, p38, NF- κ B, and AP-1 in rats. These findings suggest that EA may improve immune suppression after surgical trauma^[26].

TEAS has no risk of infections, needle induced contagious disease, and fear to stimulation and is more 'user friendly' with minimal training, which is more convenient for clinical application^[27]. However,

whether perioperative application of TEAS is able to improve postoperative immunosuppression of the patient receiving on-pump Coronary Artery Bypass Grafting (CABG) is unknown.

In the current study, we would attempt to evaluate potential TEAS-induced reversal of CABG-associated immunosuppression. Previous clinical studies have shown that whether in conscious state (i.e. preoperative or post-operative) or in anesthetic state, TEAS or EA applied to various surgical operations can produce beneficial effects, such as prevention of hyperglycaemia^[28], reduces intra-operative opioid consumption^[29], relieving post-hemorrhoidectomy-associated pain^[30], and improving immune and stress responses to surgery^[31]. In order to maximize possible benefit of TEAS, the perioperative administration (i.e. preoperative, intraoperative and postoperative) of TEAS will be chosen in our trial.

Considering that it is a preliminary mono-centric study, monocytic human leukocyte antigen (-D related) (mHLA-DR), a standardized “global” biomarker of injury or sepsis-associated immunosuppression, serves as a primary endpoint, and other laboratory parameters (e.g. IL-6, IL-10) and clinical outcomes (e.g. postoperative infectious complications, ICU stay time, and mortality) as the secondary endpoints. Monocytic HLA-DR is a MHC class II molecule and predominantly expressed on monocytes/macrophages^[32]. Its surface expression is indispensable for antigen presentation^[32]. Increased mHLA-DR expression reflects activation of immune cells, while diminished expression exhibits a phenotype with down regulation of antigen-presenting capacity and a shift from pro- to anti-inflammatory cytokine production^[33, 34]. Moreover, surface expression of mHLA-DR is crucial for induction of adaptive immune responses^[32, 35]. More importantly, accumulated clinical evidences indicated that its persisting decreased expression is associated with adverse clinical outcomes (e.g., secondary infection risk, mortality) in patients with trauma^[36], burns^[37], pancreatitis^[38, 39], solid organ transplantation^[40], hepatic^[41] or renal injury^[42], stroke^[43], myocardial infarction/heart failure, and cardiac arrest^[44-47], as well as sepsis^[48]. The same is true of cardiac surgery with CPB. The quantification of mHLA-DR expression shows the best predictive power on outcome in pediatric and adult patients. Postoperative reduced mHLA-DR was associated with increased length of ICU stay/mechanical ventilation and development of postoperative sepsis^[49, 50].

In addition, some immune indicators, such as high mobility group box-1 protein (HMGB1) and regulatory T cells (Treg), possibly related to the mechanism of TEAS would also be measured. HMGB1, originally described as a DNA-binding protein and passively released by necrotic cells and actively released by macrophages/monocytes, was discovered to be an essential cytokine that mediates the response to infection, injury, and inflammation^[51]. Our previous animal study has shown that EA can inhibit excessive release of HMGB1 following myocardial ischemia and attenuate the associated inflammatory responses and myocardial injury during reperfusion^[52]. Recently, HMGB1 was found to directly enhance immune inhibitory functions of Treg and limit the number and activity of conventional T cells^[53, 54].

Treg cells are responsible for limiting tissue damage and inflammation associated with both innate and adaptive immune responses^[55]. However, overactivation of Treg contributes to immunosuppression^[56].

For the reason that the population of Treg in PBMCs was indeed significantly increased at 48 hours and 96 hours after CABG with CPB^[57], which may contribute to CABG-associated immunosuppression, we speculate potential inhibition of excessive HMGB1 release of TEAS, consequently leading to attenuated function of Treg, may be associated with TEAS-induced reversal of immunosuppression, characterized by increased mHLA-DR.

Objectives

The primary objective of the study is to evaluate effects of perioperative TEAS on mHLA-DR expression in patients undergoing CABG with CPB.

Methods And Design

Study design

This study is a preliminary, single-center, double-blind, randomized and controlled clinical trial (number of sample, n = 88) to explore the effects of TEAS therapy on improvement of postoperative immunosuppression indicated by diminished HLA-DR expression of patients receiving CABG (Fig. 1). The trial will be commenced after ethical approval has been obtained from the Ethics Committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. All study-related procedures will be performed only after subjects have given their written informed consent. The trial is designed following the Consolidated Standards of Reporting Trials (CONSORT) guidelines, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Checklist (Additional file 1), and Standards for Reporting Interventions in Controlled Trials of Acupuncture (STRICTA) recommendations.

Participants

Current Sample size justification

We calculate the sample size from the pilot study in our hospital based on the primary outcome Human leukocyte antigen of monocyte (mHLA-DR). In the study, the expression of mHLA-DR three days after surgery was (36.17±5.42) % in the TEAS group and (27.33±3.50) % in the Sham TEAS group, with a power of 80% and 5% Type I error rate. Assuming that the dropout rate to be 10%, 88 patients (n = 44 for each group) are needed.

Subject recruitment

Patients will be recruited from the department of Thoracic and Cardiovascular surgery, at Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Potentially eligible subjects who have scheduled for CABG under CPB for coronary diseases will be invited to participate. Patients will be referred from a cardiothoracic surgeon, and then a research assistant will approach the subjects in the

general ward pre operation. Patients will be screened and consented for the study. Following the consent, eligible participants will be block randomized into two groups: □ TEAS group (n = 44) and □ sham TEAS group (n = 44). All patients will conduct a standard operative procedure and postoperative analgesia management. The patients of TEAS group will receive TEAS therapy in perioperative period, and the Sham TEAS will not be performed to receive electrical stimulation sensation in perioperative period. Assessments will be conducted during the perioperative period until 30 days after surgery.

Inclusion criteria

1. Aged 18–75 years, male and female;
2. Patients diagnosed as coronary disease, scheduled to receive CABG;
3. BMI: $18.5\text{kg}/\text{m}^2 < \text{BMI} \leq 30\text{kg}/\text{m}^2$
4. Graded as I-III by American Standards Association (ASA);
5. Patients firstly receiving CABG under extracorporeal circulation.

Exclusion Criteria

1. Presence of surgical incision or scar at Zusanli acupoint (ST35) /Shenshu (BL23) acupoint;
2. Patients with local skin infection at acupoint;
3. Patients with nerve injury on upper or lower limbs;
4. Patients with history of spinal surgery;
5. Patients who have participated in other clinical trial in recent 4 weeks;
6. Patients using pacemaker;
7. Patients combined with pain before surgery who are using central analgesic drug or drug abuser (e.g., opioid) and dependent user;
8. Patients combined with severe central nervous system disease or severe mental disease;
9. Patients with alcoholic history;
10. Patients who have received emergent coronary bypass operation due to acute myocardial infarction.

Randomization and blinding

Computer generates random number sequence. It will be printed and placed in separate sealed envelopes. The patients will be randomly divided into either the TEAS group or the sham TEAS group in a 1:1 ratio. We set the blind code in the case for remaining blind when the patients have the adverse effects. The random code and blind code will be conducted by a “third party” independent of the study using opaque envelopes. The envelopes will be sealed and shuffled and the assignment records will not be disclosed until the end of the study. Trial participants, cardiothoracic surgeon, anaesthesiologists, outcome assessors, and data analysts will be blinded to the treatment allocation to minimize potential sources of bias. Only the nurse of anesthesiology department (having received specialized acupuncture training) will

know the participants' group allocation. However, this nurse will not know any other information about the patients.

Interventions

This trial will include 2 groups: the group of TEAS and the group of transcutaneous acupoint pseudo-electric stimulation (Sham TEAS). In each group, there will be 44 patients receiving CABG with cardiopulmonary bypass. The patients of TEAS group will receive TEAS therapy in perioperative period, and the Sham TEAS will not be performed to receive electrical stimulation sensation in perioperative period.

- Selection of acupoints: Zusanli acupoint (ST36)—Shenshu acupoint (BL23) (Fig. 2 and 3)
 - Zusanli location: located at outside of the shank, 3 cun (10 cm) below Dubi acupoint (ST35) and a finger's width (middle finger) to tibial front edge;
 - Shenshu location: located below the spinous process of the second lumbar vertebra, 1.5 cun (5 cm) to the central line.
- Stimulation timing: Before anesthesia + Intraoperative + Postoperative (Fig. 4)
 - 30 mins before anesthesia: one stimulation for 30 mins;
 - Intraoperative: stimulating in the whole course;
 - Postoperative: 0–24h: 4 times of stimulation (30 mins per stimulation). 5–6 hours after the surgery (the first time), 11–12 hours after the surgery (the second time), 17–18 hours after the surgery (the third time), 23–24 hours after the surgery (the fourth time).
- TEAS parameter
 - Frequency: 2/100 Hz alternative;
 - Intensity: 15mA;
 - Low-frequency electronic pulse therapeutic device G6805–2 (Huayi, Shanghai, China) (Fig. 5):
- Current intensity: main difference between the study group and control group
 - TEAS group: the acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes (Fig 6). Selection of these acupoints was based on a consensus between the acupuncturists of the study.
 - Sham TEAS group: No electrical stimulation sensation is performed in the Sham TEAS group. In the Sham TEAS group, pseudo-stimulation is provided by deliberately connecting the electrodes to the incorrect output socket of the electroacupuncture device, and thus there is no flow of electric current. Patients could see the output light flashing but no current was transmitted

throughout the procedure. Patients would be told that the stimulation frequency selected was not perceivable by human beings.

- Anesthesia protocol
 - Medication before the anesthesia
 1. Morphine: 0.1mg/kg
 - Anesthesia induction
 1. Sufentanil 0.3–0.5ug/kg
 2. Propofol TCI: 2.0–3.5ug/ml
 3. Dextromidine 0.5–1.0ug/kg/hr or midazolam 0.05–0.1mg/kg
 4. Lidocaine 1mg/kg (Maximum dose not higher than 50 mg)
 5. Rocuronium bromide 0.9–1.2mg/kg
- Maintenance of anesthesia
 1. Narcotic analgesics: common sufentanil by 0.2–0.5ug/kg by times (i.v) or remifentanil by 0.05–0.2ug/kg/min continuous intravenous pump injection, addition of sufentanil by 10–20ug before skin incision and sternum splitting.
 2. Inhaled general anesthetics: sevoflurane and isoflurane can be inhaled discontinuously as requested with MAC 0.7–1.0.
 3. Muscle relaxant: common vecuronium bromide and rocuronium bromide, etc.
 4. After the completion of tracheal intubation, the anaesthesia machine is connected immediately, and ETCO₂ is examined, and the breathing sound of both lungs is auscultated to determine the position of endotracheal tube.
 5. Common parameters of mechanical ventilation: VT: 7–8 ml/kg, RR: 10–12 bpm; PaO₂: 200 mmHg, PaCO₂: 35–45 mmHg, FiO₂: 80%.

Outcomes

Primary outcome measures

With mHLA-DR as primary outcome of this clinical trial, the improvement of postoperative immunosuppression is evaluated.

Peripheral blood is collected from the patient to test this indicator at the following time points: One day before surgery, Day 1 after surgery (one day after surgery), Day 3 after surgery (3 days after surgery), and Day 5 after surgery (5 days after surgery).

The percentage of HLA-DR⁺/CD14⁺ cell in all CD14⁺ cells will be determined by flow cytometry (Becton-Dickinson, New Jersey, U.S.) in central lab of Shuguang hospital affiliated to Shanghai university of traditional Chinese medicine.

Secondary outcome measures

Related indicators of immunosuppression include interleukin-6 (IL-6), interleukin-10 (IL-10), C-reactive protein (CRP), postoperative infectious complications (pneumonia, incision infection and indwelled catheter infection), ICU stay time, and mortality. The examination methods and time points are as follows:

1. IL-6 and IL-10: Plasma levels of IL-6 and IL-10 will be determined using the ELISA(enzyme-linked immuno sorbent assay) with high sensitivity kits (ABCAM, Shanghai, China), one day before surgery, Day 1, 3 and 5 after surgery.
2. CRP: CRP expression level in blood samples, automatic biochemical analyzer (Beckman Coulter, Georgia, U.S.), one day before surgery, Day 1, 3 and 5 after surgery;
3. Postoperative infectious complications:

Pneumonia: Pneumonia was defined according to the Centre of Disease Control and Prevention (CDC) guidelines. Postoperative healthcare-associated pneumonia will be proven throughout adiograph suspicious for pneumonia, clinical signs and symptoms suspicious for pneumonia and positive culture from broncho-alveolar lavage, a positive blood culture not related to another infection, or a positive sputum culture.

Guidelines Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of healthcare-associated infection and criteria for specific types of infections in the acute care setting. *Am J Infect Control* 2008; 36:309–332.

Postoperative infection other than pneumonia: observe the incidence of incision infection, indwelled catheter infection after the surgery (fever, bacterial culture).

We will record postoperative infectious complications according to the patient's medical history, imaging examination, clinical signs and sputum culture within 30 days after the operation.

- ICU stay time: We will record the length of ICU stay after surgery(days (d), mean \pm standard deviation (SD)).
- Mortality: We will record a 30-day mortality rate after surgery.
- The indicators of related mechanism study include high mobility group proteins–1 (HMGB1), regulatory T-cell (Treg) and CD4+ T-cell. The examination methods and time points are as follows:
- HMGB1: HMGB1 expression level in blood samples, ELISA kit (ABCAM, Shanghai, China), one day before surgery, Day 1, 3 and 5 after surgery;
- Treg: Percentage of CD4+/CD25+ T-cell in CD4+ T-cell, flow cytometry(Becton-Dickinson, New Jersey, U.S.) one day before surgery, Day 1, 3 and 5 after surgery;
- CD4+ T-cell: CD4+ T-cell number /ml blood, flow cytometry(Becton-Dickinson, New Jersey, U.S.) one day before surgery, Day 1, 3 and 5 after surgery;

All the related indicators and the indicators of related mechanism will be tested in central lab of Shuguang hospital affiliated to Shanghai university of traditional Chinese medicine.

Statistical analysis

All statistical analyses of the data will be performed using SPSS program V.21.0 (SPSS Inc., Chicago, USA). A P value < 0.05 will be considered statistically significant. The intention-to-treat (ITT) approach will be used. Measured data will be expressed as mean \pm SD ($x \pm s$) if it obeys a normal distribution or approximate normal distribution. Median (interquartile range [IQR]) will be used if the data do not obey the normal distribution and count data will be expressed in terms of the number of cases.

To analyze the primary outcome, the expression of mHLA-DR (the percentage of HLA-DR+/CD14+ cell in all CD14+ cells) will be calculated by repeated measurement ANOVA, and the comparisons between two groups will be made using the Student's t test. For the secondary outcomes, we will use chi-square tests for categorical data and repeated measurement ANOVA or Wilcoxon rank sum test for continuous data, according to whether the data are normally distributed. The variance analysis will be performed for the difference between the two groups and within the group. The stratified analysis will be performed to control the confounding factor if necessary. Data analysis will be conducted by statisticians who are independent of the research team.

Data collection and management

The data will be collected as primary and secondary outcome measures, with above described method. All data will be saved safely in internal server of Shuguang Hospital, with complete confidentiality. The participants of this study will be cited with a code different from their real names. The data management program will be approved by the trial manager and other clinicians before the registration of the first participant.

Adverse events

The status related to adverse events is acquired according to the self-report of the patient or direct observation of clinicians or by non-

induced query of the patient, and his/her clinical safety is evaluated (see Table 1).

Table 1 Clinical safety evaluation in perioperative period

Complications in perioperative period: any of following conditions is considered as complication of perioperative period.

1	Postoperative arrhythmia	postoperative atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, ventricular flutter, cardiac arrest, atrioventricular block of II° or above, frequent atrial premature beat and ventricular premature beat significantly affecting the stability of haemodynamics (indicated in ECG)□		
2	Pneumonia	body temperature above 38.5°C (indicated in chest film);		
3	Acute lung injury	(1) acute onset, with pathogenic factors;		
		(2) oxygenation index (arterial partial pressure of oxygen/fraction of inspired oxygen, PaO ₂ /FiO ₂) <300 mmHg (1 mmHg=0.133 kPa) not referring to positive end-expiratory pressure (PEEP) level;		
		(3) frontal X-ray chest film revealed patchy shadows in both lungs;		
		(4) pulmonary artery incarceration pressure < 18 mmHg or no clinical evidence of increased pressure in left atrium;		
		(5) Acute paroxysmal respiratory failure.		
4	Pulmonary atelectasis	indicated in chest film;		
5	Intraoperative and postoperative myocardial infarction	manifestation of myocardial infarction symptoms or change of ECG ST segment, continuous increase of myocardial enzyme, especially cardiac troponin I (cTnI), accompanied with dynamic change of ST segment;		
6	Postoperative cardiac insufficiency	the postoperative cardiac output (CO) is lower than lower limit of normal value or there are symptoms and vital signs of heart failure;	(1) Left cardiac insufficiency	<p>Symptoms: dyspnea; coughing, expectoration and hemoptysis; cyanosis, fatigue and weakness;</p> <p>Vital signs: expansion of border of cardiac dullness, left lower shifting of cardiac impulse with elevating sensation. Accelerated heart rate, diastolic gallop heard in apex, alternative pulse in severe case. Moist and dry rales are heard in the bottom of both lungs. Wheezing rale and dry rales may be accompanied with secondary bronchial spasm.</p>
			(2) Right	Symptoms: reduced urine

			cardiac insufficiency	<p>volume, increased nocturnal enuresis, swelling pain in liver region or even occurrence of jaundice; inappetence, dyspepsia, nausea, vomiting and diarrhea.</p> <p>Vital signs: expansion of border of cardiac dullness, apex beating showing elevating sensation, diffuse beating range, accelerated heart rate;</p> <p>Distention of jugular vein, liver swelling with tenderness, hepatojugular reflux sign positive; pitting edema, right heart failure</p> <p>Typical vital signs of failure, mostly in the body drooping part.</p>
			(3) Whole cardiac insufficiency	Coexistence of clinical manifestations of left and right cardiac insufficiency, but principally one of them
7	Postoperative respiratory insufficiency	breath in indoor air at static conditions, and intracardiac anatomical shunt and originated from the decrease of cardiac volume are excluded; arterial <u>partial pressure of oxygen</u> (PaO ₂) is lower than 8 kPa (60 mmHg) or accompanied with <u>partial pressure of carbon dioxide</u> (PaCO ₂) higher than 6.65kPa (50 mmHg).		
8	Postoperative hemorrhage of digestive tract	including ulcer bleeding or bloody gastric content caused by mucosal ischemia of gastrointestinal tract, haematemesis, tarry stool or hemaecia;		
9	Postoperative hepatic insufficiency	severe hepatocellular damage, causing significant metabolism, secretion, synthesis, biotransformation and immune function disorder, clinical syndrome of edema in the organism, jaundice, haemorrhage, infection, renal function disorder and hepatic encephalopathy, etc.		
	Postoperative renal	rapid decrease of renal excretory function in short term, and daily mean increase of serum creatinine ≥ 44.2 $\mu\text{mol/L}$ and exacerbation		

	insufficiency	of existing renal insufficiency.
10	Postoperative infection other than lung infection	including hematogenous infection, infections of digestive tract, urinary system, wound, skin, and indwelled catheter.
11	Postoperative cerebral ischemia and hypoxic disease	including cerebral infarction, cerebral thrombosis, cerebral hemorrhage, transient cerebral ischemic attack and diffuse cerebral ischemia and hypoxic disease.
12	Prolongation of postoperative hospital stay	postoperative hospital stay exceeds 14 days.
13	Acute kidney injury	(1) the increase of plasma creatinine within 48 hours ≥ 0.3 mg/dL (≥ 26.5 $\mu\text{mol/L}$);
		(2) Plasma creatinine within 7 days ≥ 1.5 times of basic value;
		(3) Urine volume within 6 hours lower than 0.5ml/kg/h.
14	Death in perioperative period: definition	(1) Death within 30 days after surgery;
		(2) Death in hospital stay after surgery;
		(3) Death caused by surgical reasons after discharge.

Quality control

The chief surgeon of thoracic surgery department, anesthetist to implement anesthetic management, nurse of anesthesiology department to carry out TEAS (having received specialized acupuncture training) as well as blood sampling personnel of clinical lab and data recording personnel are fixed to avoid bias from human operations. Specialized acupuncture training mainly includes selection of acupoints, TEAS operation standard and procedure (see Table 2).

Table 2 TEAS operation standard and procedure

1	Determination of position	the patient takes a supine position;
2	Inspection of equipment	confirm normal operation of electric acupuncture apparatus;
3	Area and acupoint locating	the Zusanli acupoint and Shenshu acupoint are determined by feeling and pressing the point for acupuncture;
4	Local skin preparation	prepare the skin at the acupuncture point, disinfect from the center with 75% ethanol cotton ball in circle to wipe off the sebum;
5	Selection of electrode slices	select electrode slices specially used for TEAS;
6	Acupoint patching	attach the electrode slices specially used for TEAS on the acupoints, press to confirm securely attached;
7	Connection of electrode slices to equipment	connect Zusanli acupoint and <u>Shenshu</u> acupoint on one side to 2 electrodes of the same wire, and those of the other side to another 2 electrodes of the same wire; both wires are connected to the same electric acupuncture apparatus;
8	Acupoint electric stimulation	confirm the electric acupuncture apparatus is in power-up state, turn on the electric acupuncture apparatus, select corresponding parameters, and initiate TEAS therapy according to the patient's tolerance to electric stimulation;
9	Maintenance treatment	maintain electric stimulation for 30 min, instruct the patient to protect the surgery area in acupuncture pin setting process, and closely examine the patient for adverse reactions of fainting, vomiting and pain during acupuncture treatment, and symptomatic treatment is provided if any;
10	End of treatment	turn off the electric acupuncture apparatus, remove the electrode slices, and clear away connection wires. Check redness and swelling, injury on the skin for electrode slice attachment, and provide symptomatic treatment in case of occurrence above symptoms.

Discussion

The patients undergoing CABG with CPB are more prone to have immunosuppression which may lead to postoperative infectious complications and a prolonged ICU stay, even mortality. Previous studies have proved that the acupuncture was able to improve the patient's immune function. TEAS have the similar efficacy as electroacupuncture, but it is easier to operate, non-invasive and easy to accept by patients. The current study is aiming at evaluating potential TEAS-induced reversal of decreased mHLA-DR α

standardized “global” biomarker of immunosuppression and exploring the possible underlying mechanism related to TEAS.

Although the immediate clinical impact of this study is limited, its results will inform further research. Following demonstration of possible immunological efficiency, biomarker-guided immunological interventions of TEAS for immunosuppression should be performed in populations with sufficiently large sample size using relevant patient-centered clinical outcomes (e.g., mortality or infectious complications). Only in this way can we finally determine the clinical value of TEAS for counterbalancing CABG-associated immunosuppression and promote its application.

Declarations

Trial status

This is the third protocol version, updated on Oct. 31th, 2019. The recruitment began on Dec. 1, 2017 and would be completed by Dec. 31, 2019. At the time of manuscript submission, the study was in recruitment phase.

Abbreviations

TEAS: Transcutaneous electrical acupoint stimulation; GA: General anesthesia; CABG: Coronary artery bypass grafting; CPB: Cardiopulmonary bypass; mHLA-DR: Monocytic human leukocyte antigen DR; CRP: C-reaction protein; IL-6: Interleukin-6; HMGB1: High mobility group box 1; Treg: Regulatory T cell; CD4⁺ T cell: CD4 positive thymocyte cell; BMI: Body mass index; VT: Tidal volume; PCO₂: Partial pressure of carbon dioxide; PO₂: Oxygen partial pressure; RR: Respiratory rate; FiO₂: Fraction of inspiration O₂; ITT: intention-to-treat

Acknowledgements

We would like to express gratitude to the Acupuncture and Anesthesia Research Institute of Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, for help in study's organization.

Funding

The present study is supported by the project of the Shanghai Municipal Commission of Health and Family Planning (No. 20154Y0111) and the project of the National Natural Science Foundation of China (No. 81603450).

Availability of data and material

The final trial dataset will only be accessible to the study investigators.

Authors' contributions

W. T. Chen and J. F. Wei drafted the manuscript, and contributed greatly to study conception and design. L. Yuan and D. W. Zhang participated in study design, and is responsible for the formulation of TEAS operation standard and procedure. G. Q. Fu, J. Wang and Y. L. Zhou participated in study design, and is responsible for the contact of all surgeons. W. Tang is a local investigator in an involved center, and helped in the revision of the manuscript. Y. Yong participated in this study, and is responsible for blood specimen collection, determination and recording. L. Wang participated in the study, and is responsible for anesthetic management of the patients in perioperative period, and contributed greatly to the successful implementation of the study. J. G. Song and S. Wang drafted the manuscript, and contributed greatly to study conception and design. All authors strictly reviewed and approved final manuscript.

Ethics approval and consent to participate

This study has been approved by Ethics Committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine with the number 2016–455–06–01 and registered at ClinicalTrials with the Identifier NCT02933996 on 13 October 2016, <https://www.clinicaltrials.gov/ct2/show/NCT02933996>. Informed consent will be obtained from each of the participants. Patient consent was obtained.

Competing interests

The authors declare that they have no competing interests. The Ethics Committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine is independent from the sponsor and competing interests.

Consent for publication

Figure 2, 3, 4 and 5 are all produced by our institution and all rights are reserved. The patient photographed in Figure 6 is aware of this publication and has signed the patient consent form.

Author details

¹Anesthesiology Department, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China. ²Guangdong Cardiovascular Institute & Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, China. ³Shantou University Medical College, Shantou, Guangdong Province, China. ⁴Acupuncture and Anesthesia Research Institute, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

Supplementary File Legend

Additional file 1: SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents. (PDF 200 kb).

References

1. Butler, J., G. M. Ricker, and S. Westaby, *Inflammatory response to cardiopulmonary bypass*. *Ann Thorac Surg*, 1993. 55(2): p. 552–9.
2. Kollef, M. H., et al., *The impact of nosocomial infections on patient outcomes following cardiac surgery*. *Chest*, 1997. 112(3): p. 666–75.
3. Hortal, J., et al., *Ventilator-associated pneumonia in patients undergoing major heart surgery: an incidence study in Europe*. *Crit Care*, 2009. 13(3): p. R80.
4. Bouza, E., et al., *Infections following major heart surgery in European intensive care units: there is room for improvement (ESGNI 007 Study)*. *J Hosp Infect*, 2006. 63(4): p. 399–405.
5. Leal-Noval, S. R., et al., *Nosocomial pneumonia in patients undergoing heart surgery*. *Crit Care Med*, 2000. 28(4): p. 935–40.
6. Kirklin, J. K., et al., *Complement and the damaging effects of cardiopulmonary bypass*. *J Thorac Cardiovasc Surg*, 1983. 86(6): p. 845–57.
7. Sawa, Y., et al., *Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations*. *J Thorac Cardiovasc Surg*, 1996. 111(1): p. 29–35.
8. Kharazmi, A., et al., *Endotoxemia and enhanced generation of oxygen radicals by neutrophils from patients undergoing cardiopulmonary bypass*. *J Thorac Cardiovasc Surg*, 1989. 98(3): p. 381–5.
9. Landow, L. and L. W. Andersen, *Splanchnic ischaemia and its role in multiple organ failure*. *Acta Anaesthesiol Scand*, 1994. 38(7): p. 626–39.
10. Hall, R. I., M. S. Smith, and G. Ricker, *The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations*. *Anesth Analg*, 1997. 85(4): p. 766–82.
11. Butler, J., et al., *Effect of cardiopulmonary bypass on systemic release of neutrophil elastase and tumor necrosis factor*. *J Thorac Cardiovasc Surg*, 1993. 105(1): p. 25–30.
12. Hill, G. E., *Cardiopulmonary bypass-induced inflammation: is it important?* *J Cardiothorac Vasc Anesth*, 1998. 12(2 Suppl 1): p. 21–5.
13. Stoppelkamp, S., et al., *Identification of Predictive Early Biomarkers for Sterile-SIRS after Cardiovascular Surgery*. *PLoS One*, 2015. 10(8): p. e0135527.
14. Hadley, J. S., et al., *Alterations in inflammatory capacity and TLR expression on monocytes and neutrophils after cardiopulmonary bypass*. *Shock*, 2007. 27(5): p. 466–73.

- 15.Naldini, A., et al., *In vitro cytokine production and T-cell proliferation in patients undergoing cardiopulmonary by-pass*. Cytokine, 1995. 7(2): p. 165–70.
- 16.Lee, H., et al., *Acupuncture for symptom management of rheumatoid arthritis: a pilot study*. Clin Rheumatol, 2008. 27(5): p. 641–5.
- 17.Ng, D. K., et al., *A double-blind, randomized, placebo-controlled trial of acupuncture for the treatment of childhood persistent allergic rhinitis*. Pediatrics, 2004. 114(5): p. 1242–7.
- 18.Biernacki, W. and M. D. Peake, *Acupuncture in treatment of stable asthma*. Respir Med, 1998. 92(9): p. 1143–5.
- 19.Yang, L., et al., *Cardioprotective effects of electroacupuncture pretreatment on patients undergoing heart valve replacement surgery: a randomized controlled trial*. Ann Thorac Surg, 2010. 89(3): p. 781–6.
- 20.Ni, X., et al., *Cardioprotective effect of transcutaneous electric acupoint stimulation in the pediatric cardiac patients: a randomized controlled clinical trial*. Paediatr Anaesth, 2012. 22(8): p. 805–11.
- 21.Wang, J., et al., *Electroacupuncture suppresses surgical trauma stress-induced lymphocyte apoptosis in rats*. Neurosci Lett, 2005. 383(1–2): p. 68–72.
- 22.Cheng XD, W. G., et al., *Dynamic observation on regulation of electroacupuncture on the proliferation responses of spleen lymphocytes from traumatized rats*. Chin J Immunol, 1997(13): p. 68–70.
- 23.Cheng, X. D., et al., *Effect of continued electroacupuncture on induction of interleukin–2 production of spleen lymphocytes from the injured rats*. Acupunct Electrother Res, 1997. 22(1): p. 1–8.
- 24.XD, C., *Involvement of orphanin FQ in electroacupuncture modulation on immunosuppression by trauma*. Zhen Ci Yan Jiu, 2001(26): p. 219–20.
- 25.Yu, Y., et al., *Role of endogenous interferon-gamma on the enhancement of splenic NK cell activity by electroacupuncture stimulation in mice*. J Neuroimmunol, 1998. 90(2): p. 176–86.
- 26.Wang, K., et al., *The effects of electroacupuncture on TH1/TH2 cytokine mRNA expression and mitogen-activated protein kinase signaling pathways in the splenic T cells of traumatized rats*. Anesth Analg, 2009. 109(5): p. 1666–73.
- 27.Zhang, Q., et al., *The effect of pre-treatment with transcutaneous electrical acupoint stimulation on the quality of recovery after ambulatory breast surgery: a prospective, randomised controlled trial*. Anaesthesia, 2014. 69(8): p. 832–9.
- 28.Man, K. M., et al., *Transcutaneous electrical nerve stimulation on ST36 and SP6 acupoints prevents hyperglycaemic response during anaesthesia: a randomised controlled trial*. Eur J Anaesthesiol, 2011. 28(6): p. 420–6.

29. Wang, H., et al., *Transcutaneous electric acupoint stimulation reduces intra-operative remifentanyl consumption and alleviates postoperative side-effects in patients undergoing sinusotomy: a prospective, randomized, placebo-controlled trial*. Br J Anaesth, 2014. 112(6): p. 1075–82.
30. Yeh, M. L., et al., *Effect of Transcutaneous Acupoint Electrical Stimulation on Post-Hemorrhoidectomy-Associated Pain, Anxiety, and Heart Rate Variability: A Randomized-Controlled Study*. Clin Nurs Res, 2018. 27(4): p. 450–466.
31. Grech, D., et al., *Intraoperative Low-frequency Electroacupuncture under General Anesthesia Improves Postoperative Recovery in a Randomized Trial*. J Acupunct Meridian Stud, 2016. 9(5): p. 234–241.
32. Roche, P. A. and K. Furuta, *The ins and outs of MHC class II-mediated antigen processing and presentation*. Nat Rev Immunol, 2015. 15(4): p. 203–16.
33. Hotchkiss, R. S., G. Monneret, and D. Payen, *Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach*. Lancet Infect Dis, 2013. 13(3): p. 260–8.
34. Monneret, G., et al., *Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony*. Mol Med, 2008. 14(1–2): p. 64–78.
35. Boomer, J. S., et al., *Immunosuppression in patients who die of sepsis and multiple organ failure*. JAMA, 2011. 306(23): p. 2594–605.
36. Cheron, A., et al., *Lack of recovery in monocyte human leukocyte antigen-DR expression is independently associated with the development of sepsis after major trauma*. Crit Care, 2010. 14(6): p. R208.
37. Venet, F., et al., *Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: Correlation with severity and secondary septic shock*. Crit Care Med, 2007. 35(8): p. 1910–7.
38. Ho, Y. P., et al., *A strong association between down-regulation of HLA-DR expression and the late mortality in patients with severe acute pancreatitis*. Am J Gastroenterol, 2006. 101(5): p. 1117–24.
39. Satoh, A., et al., *Human leukocyte antigen-DR expression on peripheral monocytes as a predictive marker of sepsis during acute pancreatitis*. Pancreas, 2002. 25(3): p. 245–50.
40. Reinke, P., et al., *Late acute rejection in long-term renal allograft recipients. Diagnostic and predictive value of circulating activated T cells*. Transplantation, 1994. 58(1): p. 35–41.
41. Antoniadou, C. G., et al., *Reduced monocyte HLA-DR expression: a novel biomarker of disease severity and outcome in acetaminophen-induced acute liver failure*. Hepatology, 2006. 44(1): p. 34–43.
42. Ahlstrom, A., et al., *Predictive value of interleukins 6, 8 and 10, and low HLA-DR expression in acute renal failure*. Clin Nephrol, 2004. 61(2): p. 103–10.

- 43.Meisel, A., et al., *Predicting post-stroke infections and outcome with blood-based immune and stress markers*. Cerebrovasc Dis, 2012. 33(6): p. 580–8.
- 44.Venet, F., et al., *Decreased Monocyte HLA-DR Expression in Patients After Non-Shockable out-of-Hospital Cardiac Arrest*. Shock, 2016. 46(1): p. 33–6.
- 45.Haeusler, K. G., et al., *Immune responses after acute ischemic stroke or myocardial infarction*. Int J Cardiol, 2012. 155(3): p. 372–7.
- 46.Schefold, J. C., et al., *Heart failure and kidney dysfunction: epidemiology, mechanisms and management*. Nat Rev Nephrol, 2016. 12(10): p. 610–23.
- 47.von Haehling, S., et al., *Leukocyte redistribution: effects of beta blockers in patients with chronic heart failure*. PLoS One, 2009. 4(7): p. e6411.
- 48.Monneret, G., et al., *Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock*. Intensive Care Med, 2006. 32(8): p. 1175–83.
- 49.Franke, A., et al., *Delayed recovery of human leukocyte antigen-DR expression after cardiac surgery with early non-lethal postoperative complications: only an epiphenomenon?* Interact Cardiovasc Thorac Surg, 2008. 7(2): p. 207–11.
- 50.Allen, M. L., et al., *Early postoperative monocyte deactivation predicts systemic inflammation and prolonged stay in pediatric cardiac intensive care*. Crit Care Med, 2002. 30(5): p. 1140–5.
- 51.Bianchi, M. E. and A. A. Manfredi, *High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity*. Immunol Rev, 2007. 220: p. 35–46.
- 52.Zhang, J., et al., *Vagal modulation of high mobility group box–1 protein mediates electroacupuncture-induced cardioprotection in ischemia-reperfusion injury*. Sci Rep, 2015. 5: p. 15503.
- 53.Wild, C. A., et al., *HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells*. Int Immunol, 2012. 24(8): p. 485–94.
- 54.Zhang, Y., et al., *The potential effect and mechanism of high-mobility group box 1 protein on regulatory T cell-mediated immunosuppression*. J Interferon Cytokine Res, 2011. 31(2): p. 249–57.
- 55.Shevach, E. M., et al., *Control of T-cell activation by CD4+ CD25+ suppressor T cells*. Immunol Rev, 2001. 182: p. 58–67.
- 56.Allan, S. E., et al., *CD4+ T-regulatory cells: toward therapy for human diseases*. Immunol Rev, 2008. 223: p. 391–421.
- 57.Yeh, C. H., et al., *Induced interleukin–19 contributes to cell-mediated immunosuppression in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass*. Ann Thorac Surg, 2011. 92(4):

Figures




Figure 1

Study design and participant flow chart. CABG under extracorporeal circulation




Figure 2

Zusanli (ST36) illustration




Figure 3

Shenshu (BL23) illustration




Figure 4

Illustration of the timing for TEAS intervention in perioperative period



Figure 5




Figure 6

Acupoints selected in this trial. A: Intraoperative Zusanli acupoint (ST36) TEAS therapy; B: Intraoperative Shenshu acupoint (BL23) TEAS therapy; C: Intraoperative bilateral Zusanli acupoint (ST36) + Shenshu acupoint (BL23) TEAS therapy.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [ResearchChecklist.pdf](#)